Dolcet X, et al. (2006) Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 281, 22118-30 16735506

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S32-p - IkB-alpha (human) ▲

Modsite: LLDDRHDsGLDsMkD SwissProt Entrez-Gene Orthologous residues IkB‑alpha (human): S32‑p, IkB‑alpha (mouse): S32‑p, IkB‑alpha (rat): S32‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma Relevant cell lines - cell types - tissues:  endometrium, Ishikawa (endometrial) Cellular systems studied:  cell lines, primary cells Species studied:  human Comments:  KLE, RL-95, and HEC-1-A cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MG132 increase bortezomib increase siRNA bortezomib IKKB (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  transcription, induced

S36-p - IkB-alpha (human) ▲
Modsite: RHDsGLDsMkDEEyE SwissProt Entrez-Gene Orthologous residues IkB‑alpha (human): S36‑p, IkB‑alpha (mouse): S36‑p, IkB‑alpha (rat): S36‑p Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  transcription, induced

S176-p - IKKA (human) ▲

Modsite: AKDVDQGsLCtsFVG SwissProt Entrez-Gene Orthologous residues IKKA (human): S176‑p, IKKA (mouse): S176‑p, IKKA (rat): S176‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma Relevant cell lines - cell types - tissues:  endometrium, Ishikawa (endometrial) Cellular systems studied:  cell lines, primary cells Species studied:  human Comments:  KLE, RL-95, and HEC-1-A cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes bortezomib increase

S180-p - IKKA (human) ▲

Modsite: DQGsLCtsFVGTLQY SwissProt Entrez-Gene Orthologous residues IKKA (human): S180‑p, IKKA (mouse): S180‑p, IKKA (rat): S180‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma Relevant cell lines - cell types - tissues:  endometrium, Ishikawa (endometrial) Cellular systems studied:  cell lines, primary cells Species studied:  human Comments:  KLE, RL-95, and HEC-1-A cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes bortezomib increase

S177-p - IKKB (human) ▲

Modsite: AkELDQGsLCtsFVG SwissProt Entrez-Gene Orthologous residues IKKB (human): S177‑p, IKKB (mouse): S177‑p, IKKB (rat): S177‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma Relevant cell lines - cell types - tissues:  endometrium, Ishikawa (endometrial) Cellular systems studied:  cell lines, primary cells Species studied:  human Comments:  KLE, RL-95, and HEC-1-A cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes bortezomib increase

S181-p - IKKB (human) ▲

Modsite: DQGsLCtsFVGTLQy SwissProt Entrez-Gene Orthologous residues IKKB (human): S181‑p, IKKB (mouse): S181‑p, IKKB (rat): S181‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma Relevant cell lines - cell types - tissues:  endometrium, Ishikawa (endometrial) Cellular systems studied:  cell lines, primary cells Species studied:  human Comments:  KLE, RL-95, and HEC-1-A cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes bortezomib increase

S536-p - NFkB-p65 (human) ▲

Modsite: sGDEDFSsIADMDFS SwissProt Entrez-Gene Orthologous residues NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma Relevant cell lines - cell types - tissues:  endometrium, Ishikawa (endometrial) Cellular systems studied:  cell lines, primary cells Species studied:  human Comments:  KLE, RL-95, and HEC-1-A cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes MG132 increase LLnL increase epoxomicin increase bortezomib increase siRNA bortezomib IKKA (human) inhibit treatment-induced increase siRNA bortezomib IKKB (human) inhibit treatment-induced increase